| CAS NO: | 62613-82-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| Molecular Weight (MW) | 158.16 |
|---|---|
| Formula | C6H10N2O3 |
| CAS No. | 62613-82-5 (Oxiracetam); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 31 mg/mL (196.0 mM) |
| Water: 31 mg/mL (196.0 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 4-Hydroxy-2-oxopyrrolidine-N-acetamide InChi Key: IHLAQQPQKRMGSS-UHFFFAOYSA-N InChi Code: InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10) SMILES Code: O=C(N)CN1C(CC(O)C1)=O |
| Synonyms | ISF 2522; ISF2522; ISF-2522; Neuractiv; Hydroxypiracetam; |
| In Vitro | In vitro activity: Oxiracetam (also known as ISF 2522), a cyclic derivative of gamma-aminobutyric acid (GABA), is used as a nootropic drug to improve memory and learning. |
|---|---|
| In Vivo | Oxiracetam (50 mg/kg i.p.) improves avoidance acquisition in BALB/c mice. Oxiracetam (100 mg/kg i.p.) reduces the scopolamine-induced amnesic effect and decrease in acetylcholine level in the cortex and hippocampus. Oxiracetam pretreatment (30 mg/kg) prevents social recognition deficits produced with trimethyltin in rats. |
| Animal model | BALB/c mice |
| Formulation & Dosage | 50 mg/kg i.p. |
| References | Arch Int Pharmacodyn Ther. 1985 May;275(1):86-92; Pharmacol Biochem Behav. 1987 Jul;27(3):491-5. |
m.cnreagent.com